Liquidia loses patent infringement ruling for YUTREPIA
A district court ruled two claims of Liquidia's '327 patent for YUTREPIA valid and infringed, triggering a possible injunction against the drug's PH-ILD indication, though Liquidia plans to appeal. The company stated the potential financial impact is uncertain.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed